Karyopharm enters collaboration with Ivy Brain Tumor Center
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics to accelerate the treatment of brain cancer. The Ivy Brain Tumor Center will employ Karyopharm's oral Selective Inhibitor of Nuclear Export, or SINE, compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma. "This academic-private partnership will begin with a preclinical study targeting the protein XP01 in glioblastoma patients and testing several new drug cocktails involving selinexor. Based on detailed pharmacodynamic and pharmacokinetic analyses, the lead drug cocktail will then be pursued as a combined-drug trial within the Ivy Brain Tumor Center's Phase 0 clinical trial portfolio. This unique trial format will enable researchers to understand if the experimental therapy is impacting an individual patient's brain tumor in as little as seven days, therefore saving valuable patient time."